您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。 营销材料 – 欧洲大陆中小盘股 - 德意志银行 | 发现报告

营销材料 – 欧洲大陆中小盘股

2026-08-29 德意志银行 Joker Chan
报告封面

Marketing Slides–Continental European SMIDs September 2026 Michael Kuhn | LarsvomCleff| Olivia Pulvermacher | Manuela Stuerzer Coverage Overview Authors Research Analystolivia.pulvermacher@db.com+49 69 910-31944 AlzchemGroup AGNeste OyjVerbio SE DACH Small & Mid Cap ValuationOverview Aixtron SE Outlook AIXTRONSEisaleadingproviderofMOCVDequipmentfortheproductionofcompoundsemi-conductors,positioning it at the heart of several long-term structural growth trends in powerelectronicsandoptoelectronics.Managementhasclearlyframed2026asatransitionyear,withasignificantproductmixshiftwhereacyclicaltroughinsiliconcarbide(SiC)toolsisbeingoffsetbyastrongupcycleinoptoelectronics(lasers)drivenbyAIdatacenterdemand.Webelievethisdynamiccreatesanattractivescenarioforinvestors.Whilenear-termvisibilityislimited,themarkethasnowresetitsexpectations.Lookingto 2027 and beyond,we anticipate a multi-pronged growth re-acceleration.Thecurrentstrengthinthelaserbusinessissettocontinue,complementedbytheanticipatedadoptionofgalliumnitride(GaN)forAIdatacenterpowerarchitecturesandacyclicalrecoveryintheSiCmarketasEV-relatedovercapacityisabsorbed.Atthesametime,sharesaretradingatmulti-yearvaluationhighs,suggestingthatthegrowthpotentialismostlyreflectedintheshareprice,andweseeabalancedrisk-returnprofile.Basedonthisassessment,werateAixtronaHold.Valuation Wevaluethestockbasedon26xFY28P/E.ThisisinlinewithAixtron’shistorical1yforwardmedianvaluation,reflectingourviewthatthemarketisincreasinglywillingtotreatAixtronasa"conceptstock,"focusedonitslong-termgrowthoptionalitiesratherthannear-termcyclicality.Thetargetmultiplecomparestoa(post-Covid)tradingrangeof10xto40x,andputsAixtrononadiscounttofaster-growingsemicappeerstradingat>30x.Risk Share price performance Generalrisksincludefluctuationsinthebroadereconomicenvironmentandshiftsinthecompetitivelandscape,whichcouldpresentbothopportunitiesandchallenges.Company-specificrisksthatcouldimpactperformanceinclude:(1)SiCMarketDynamics:Aprolongedordeeper-than-expectedcyclicaldownturnintheSiCmarketcoulddelayarecoveryintooldemandbeyond2027(downside).Conversely,aquicker-than-expectedrecoveryintheSiCmarket,drivenbyacceleratedEVadoptionornewusecases,couldprovideearlierupside(upside).(2)GaNAdoptioninAIDataCenters:Slower-than-anticipatedadoptionofGaNinAIdatacenterpowerarchitecturescouldpushoutthiskeygrowthcatalyst(downside).However,faster-than-expectedpenetrationorbroaderapplicationsofGaNin this segment could significantly accelerate demand(upside).(3)AI-Driven OpticalInterconnectBuild-out:AslowdownintheAI-drivenopticalinterconnectbuild-outcoulddampenthecurrentstrengthintheoptoelectronicssegment(downside).Anaccelerationorsustainedstrongdemandinthisarea,potentiallyfueledbynewtechnologiesorcustomerwins,couldfurtherboostoptoelectronics(upside).(4)Competition:IncreasedcompetitionfromlocaltoolmanufacturersinChinacouldleadtomarketsharelossorpricingpressure(downside).Aixtron'sabilitytomaintainitstechnologicalleadershipanddifferentiateitsmulti-waferplatformscouldmitigatethisriskorevenleadtomarketsharegains(upside).(5)ForeignExchangeMovements:Unfavorableforeignexchangemovements,particularlyaweakerUSDollar,couldnegativelyimpactreportedmargins(downside).Conversely,favorableFXmovementscouldprovideatailwindtoprofitability(upside). Source: Deutsche Bank estimates, Bloomberg Finance LP Aixtron SE Aixtron SE Aixtron SE Aixtron SE AlzchemGroupAG Outlook AlzchemGroupAG,foundedin1908,isaspecializedGermanchemicalscompanywithauniquepositionin the calcium carbide/calcium cyanide(NCN)value chain.Its vertically integrated"Verbundsystem"links raw materials and intermediates with downstream specialty products,supportingsecurityofsupply,costefficiencyandflexibility.ThecoreoftheinvestmentcaseisAlzchem'sexposure to two structurally growing,high-margin specialty products:creatine andnitroguanidine,forwhich itis theexclusiveWestern market leader.Weexpect bothto be keyearningsdriversoverthecomingyears,withEBITDAmarginscloseto40%.Alzchemisstrategicallypositionedtocapitalizeonsecularmegatrendslikehealthyaging,globalpopulationgrowth,safety&defense,andclimateprotection/renewableenergy.Thecompany'ssignificantcapacityexpansionplans,backedbycustomerandgovernmentgrants,forbothcreatineandnitroguanidine,underpinacompellingmulti-yeargrowthstory.Weforecaststrongearningstrajectory,with11%SalesCAGRand14%EBITDACAGRfor2025-2030E. Valuation OurtargetpriceisbasedonaDCFvaluation,back-testedwithpeermultiples.KeyDCFparametersincludea6.8%WACCanda1.5%terminalgrowthrate,broadlyinlinewithlong-termGDPgrowthexpectationsformaturemarkets.Thistargetpriceimpliesa20.3xEV/EBITDAand37.3xP/EforFY26E,easingto13.9xEV/EBITDAand27.4xP/EforFY28E. Risk Share price performance MajorrisksincludeAsiancompetition,pesticideexportcontroversyregardingcyanamide,volatileenergycosts,substitution risk,demand volatility,legal andregulatory uncertainties,productionshortages,supplychainvolatility,financialrisks(e.g.,currency),andglobaleconomicdownturns.Alzchememploys various strat